Treatment of Crohn’s disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab , but at considerable cost. A recent analysis of results from 11 published studies including 829 patients shows that a new and lower-cost biosimilar for infliximab-called CT-P13 -has excellent clinical efficacy and safety.